Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908177061> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W2908177061 abstract "858 Background: TAS-102 significantly improved progression free survival (PFS) and overall survival (OS) versus placebo in patients with treatment refractory mCRC. We analyzed potential predictive and prognostic factors in patients treated with TAS-102 in real-world practice. Methods: We retrospectively evaluated the clinical data of 129 patients who received TAS-102. Different factors associated with PFS and OS were analyzed. Results: Baseline characteristics were: median age 67 (range 37-83), male 63.6%, ECOG PS 0 in 40.3% and 1 in 59.7%. Primary tumor location: right 20.2%, left 79.2%, wt RAS 45%. Median number of TAS-102 treatment line 3 (range 2-8). Prior treatment: anti-EGFR 45%, anti-VEGF 83%, and regorafenib 20.9%. Median follow-up was 9.4 months. The median number of cycles of TAS-102 was 3 (range 1-14). Best achieved response was SD in 23%. Median PFS was 3.3 months and OS was 11.1 months. Any ≥ grade 3 AE was in 45%, the most common ≥ grade 3 AEs were neutropenia (40.2%), anemia (6.2%), thrombocytopenia (4.7%), febrile neutropenia (2.3%), diarrhea (1.6%), nausea (1.6%), and asthenia (1.6%). Dose reduction was needed in 29.5% and cycle delay in 53.5%. Factors significantly associated with longer PFS were: initiation of TAS-102 treatment more than 3 months from last fluoropyrimidine therapy (p = 0.022, HR 0.633), normal baseline CRP level (p = 0.004, HR 0.479), baseline WBC < 8 × 10 9 /L (p = 0.025, HR 0.641), monocytes < 0.5 × 10 9 /L (p = 0.016, HR 0.522), neutropenia ≥ grade 2 during treatment (p < 0.0001, HR 0.349), TAS-102 dose reduction during treatment (p < 0.0001, HR 0.397), and TAS-102 cycle delay (p < 0.0001, HR 0.402). Factors associated with longer OS were normal CRP (p = 0.001, HR 0.295), normal LDH (p = 0.006, HR 0.422), WBC < 8 × 10 9 /L (p = 0.0001, HR 0.357), monocytes < 0.5 × 10 9 /L (p = 0.016, HR 0.373), neutropenia ≥ G2 during treatment (p = 0.0002, HR 0.343), TAS-102 cycle delay (p = 0.002, HR 0.421), wt RAS (p = 0.05, HR 0.578). Conclusions: This analysis confirms that TAS-102 is effective in patients with refractory mCRC treated in a real-world setting. Factors associated with better outcomes were baseline CRP, WBC, monocytes, and neutropenia, dose reduction and cycle delays during the treatment." @default.
- W2908177061 created "2019-01-11" @default.
- W2908177061 creator A5000705184 @default.
- W2908177061 creator A5025931905 @default.
- W2908177061 creator A5030927116 @default.
- W2908177061 creator A5039421731 @default.
- W2908177061 creator A5060115847 @default.
- W2908177061 creator A5060489230 @default.
- W2908177061 creator A5061781467 @default.
- W2908177061 creator A5076719276 @default.
- W2908177061 creator A5086971449 @default.
- W2908177061 date "2018-02-01" @default.
- W2908177061 modified "2023-09-27" @default.
- W2908177061 title "Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC)." @default.
- W2908177061 doi "https://doi.org/10.1200/jco.2018.36.4_suppl.858" @default.
- W2908177061 hasPublicationYear "2018" @default.
- W2908177061 type Work @default.
- W2908177061 sameAs 2908177061 @default.
- W2908177061 citedByCount "0" @default.
- W2908177061 crossrefType "journal-article" @default.
- W2908177061 hasAuthorship W2908177061A5000705184 @default.
- W2908177061 hasAuthorship W2908177061A5025931905 @default.
- W2908177061 hasAuthorship W2908177061A5030927116 @default.
- W2908177061 hasAuthorship W2908177061A5039421731 @default.
- W2908177061 hasAuthorship W2908177061A5060115847 @default.
- W2908177061 hasAuthorship W2908177061A5060489230 @default.
- W2908177061 hasAuthorship W2908177061A5061781467 @default.
- W2908177061 hasAuthorship W2908177061A5076719276 @default.
- W2908177061 hasAuthorship W2908177061A5086971449 @default.
- W2908177061 hasConcept C121332964 @default.
- W2908177061 hasConcept C121608353 @default.
- W2908177061 hasConcept C126322002 @default.
- W2908177061 hasConcept C142424586 @default.
- W2908177061 hasConcept C143998085 @default.
- W2908177061 hasConcept C526805850 @default.
- W2908177061 hasConcept C71924100 @default.
- W2908177061 hasConcept C87355193 @default.
- W2908177061 hasConceptScore W2908177061C121332964 @default.
- W2908177061 hasConceptScore W2908177061C121608353 @default.
- W2908177061 hasConceptScore W2908177061C126322002 @default.
- W2908177061 hasConceptScore W2908177061C142424586 @default.
- W2908177061 hasConceptScore W2908177061C143998085 @default.
- W2908177061 hasConceptScore W2908177061C526805850 @default.
- W2908177061 hasConceptScore W2908177061C71924100 @default.
- W2908177061 hasConceptScore W2908177061C87355193 @default.
- W2908177061 hasLocation W29081770611 @default.
- W2908177061 hasOpenAccess W2908177061 @default.
- W2908177061 hasPrimaryLocation W29081770611 @default.
- W2908177061 isParatext "false" @default.
- W2908177061 isRetracted "false" @default.
- W2908177061 magId "2908177061" @default.
- W2908177061 workType "article" @default.